Taiho Ventures backs early-stage therapeutics — preclinical through proof of concept — in oncology, immunology, and urology.
Patient capital from a $400M fund and a hundred-year operating company.
We invest preclinical through proof of concept. We co-lead. We rarely lead alone.
We invest at preclinical through proof of concept. We co-lead. We rarely lead alone. That is the point.
Capital is one input. The other inputs sit on the cap table beside it: a global pharmaceutical company that has read the data, agrees with the science, and intends to be useful for a decade.
- Oncology
- Immunology
- Urology
- Preclinical
- IND-enabling
- Phase 1
- Proof of Concept
- Small Molecules
- Biologics
- Gene & Cell Therapy
Twenty-three companies. Selected for science, not stage.
The cap table is the product.
We syndicate alongside funds that do this work full-time. We bring a different thing — a patient balance sheet, a development organization, and a path into Asia.
A round we co-lead is a round in which the conviction is shared. The portfolio is built that way on purpose.
Five investors. All five operating in oncology drug development before they invested in it.
- №01 · joined 2016
Sakae Asanuma
President & CEO
CFA, MBA
- №02 · joined 2016
Seiji Miyahara
Partner & Senior Investment Director
Ph.D.
- №03 · joined 2019
Takaaki Ishii
Senior Investment Director
M.S.
- №04 · joined 2022
Hidefumi Kasuga
Investment Director
Ph.D.
- №05 · joined 2024
Takayuki Hirano
Associate Investment Director
Ph.D.
Portraits live one level deeper, with the bio. The team page is names and credentials.
Begin a conversation.
We read every memo. The fastest path is one page: stage, modality, therapeutic area, and what you would do with our capital.
Submit your thesis →